AstraZeneca, Sanofi to supply 230,000 more RSV infant shots to US market

The makers of a respiratory syncytial virus (RSV) immunization for infants that has been in tight supply will deliver an additional 230,000 doses in January, the White House said on Thursday, after U.S. government officials met with the companies to discuss meeting winter demand.